The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma
Authors:
- Minggang SuMSMinggang Su
- Russell Oliver KosikRKRussell Oliver Kosik
- Liqun ZouLZLiqun Zou
- Ming JiangMJMing Jiang
- Rong TianRTRong Tian
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (10) , 767-773
Abstract
The prognostic value of FDG PET/CT in extranodal natural killer/T-cell lymphoma (ENKTL) is still controversial. Furthermore, the utility of the Deauville 5-point scale (DS) in ENKTL is uncertain. Therefore, we designed a prospective study to examine the prognostic value of 3 methods of PET/CT analysis (International Harmonization Project [IHP] criteria, DS, and SUV-based assessment). Sixty patients with newly diagnosed untreated ENKTL were enrolled. PET/CT evaluation was performed before initial treatment (pretreatment) and midtreatment (interim). Interim PET/CT response was determined based on IHP criteria, DS, and change in FDG uptake (ΔSUVmax). International Harmonization Project criteria, DS, and ΔSUVmax were then examined for the ability to predict progression-free survival (PFS) and overall survival (OS). Over a median follow-up of 23.5 months, interim PET/CT based on DS and ΔSUVmax were significant predictors of PFS and OS. After multivariate analysis, DS was an independent predictor of PFS (P < 0.001) and OS (P < 0.001). ΔSUVmax was an independent predictor of OS (P = 0.013) but not PFS (P = 0.054) and with a lower accuracy and positive predictive value than DS. Interim PET/CT analysis with DS predicts unfavorable treatment outcomes of ENKTL patients, whereas interim PET/CT analysis based on IHP criteria and SUV-based assessment have limited prognostic value.Keywords
This publication has 33 references indexed in Scilit:
- Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus RituximabJournal of Clinical Oncology, 2012
- Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission TomographyAdvances in Hematology, 2010
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 studyBlood, 2010
- Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas – the PETAL trialLeukemia & Lymphoma, 2009
- Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of ChemotherapyJournal of Nuclear Medicine, 2009
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009
- Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual AnalysisJournal of Nuclear Medicine, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphomaAnnals of Oncology, 2005
- Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphomaAnnals of Oncology, 2005